Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
Molecular Cancer Therapeutics|June 23, 2012
Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trialsRodrigo Dienstmann, Danila Serpico, Jordi Rodon, et al.
The Oncologist|November 8, 2025
Fertility preservation practices and gastrointestinal oncologist in Europe: a pan-European studyIrit Ben-Aharon, Tal Goshen-Lago, Alberto Puccini, et al.
Future Oncology (London, England)|November 10, 2020
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811Hyun Cheol Chung, Yung-Jue Bang, Charles S Fuchs, et al.
The Oncologist|April 28, 2018
Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with TrastuzumabAsunción Díaz-Serrano, Barbara Angulo, Carolina Dominguez, et al.
Targeted Oncology|October 26, 2017
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced CancerZev A Wainberg, Maria Alsina, Heloisa P Soares, et al.
BMC Primary Care|October 4, 2023
Perceptions and attitudes regarding delayed antibiotic prescription for respiratory tract infections: a qualitative studyGemma Mas-Dalmau, Sandra Pequeño-Saco, Mariam de la Poza-Abad, et al.
Cancers|September 23, 2022
Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA VaccinationMiriam Echaide, Ibone Labiano, Marina Delgado, et al.
Scientific Reports|June 17, 2026
Insights into ctDNA assessment to detect minimal residual disease (MRD) in localized colorectal cancerIbone Labiano, David Guerrero-Setas, Ana Elsa Huerta, et al.
European Journal of Cancer (Oxford, England : 1990)|April 4, 2016
Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectivesMarkus Moehler, Maike Delic, Katrin Goepfert, et al.
Investigational New Drugs|February 12, 2017
Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase CKhaldoun Almhanna, Maria Luisa Limon Miron, David Wright, et al.
Pageof 8